The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALLERGAN PLC | SHS | G0177J108 | 3,334 | 20,000 | SH | SOLE | 20,000 | 0 | 0 | ||
| AMARIN CORP PLC | SPONS ADR NEW | 023111206 | 1,545 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| AMARIN CORP PLC | SPONS ADR NEW | 023111206 | 309 | 100,000 | SH | Call | SOLE | 100,000 | 0 | 0 | |
| ANTARES PHARMA INC | COM | 036642106 | 258 | 100,000 | SH | Call | SOLE | 100,000 | 0 | 0 | |
| ANTARES PHARMA INC | COM | 036642106 | 258 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| APRICUS BIOSCIENCES INC | COM NEW | 03832V307 | 39 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| FLUIDIGM CORP DEL | COM | 34385P108 | 2,682 | 450,000 | SH | SOLE | 450,000 | 0 | 0 | ||
| GILEAD SCIENCES INC | COM | 375558103 | 7,084 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| GLAXOSMITHKLINE PLC | SPONSORED ADR | 37733W105 | 4,031 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| NOVELION THERAPEUTICS INC | COM NEW | 67001K202 | 4,833 | 1,313,387 | SH | SOLE | 1,313,387 | 0 | 0 | ||
| PROSHARES TR | ULTSH NASD BIOT | 74347B789 | 2,921 | 150,000 | SH | SOLE | 150,000 | 0 | 0 | ||
| TYME TECHNOLOGIES INC | COM | 90238J103 | 6,557 | 2,075,000 | SH | SOLE | 2,075,000 | 0 | 0 | ||
| VIKING THERAPEUTICS INC | COM | 92686J106 | 1,424 | 150,000 | SH | SOLE | 150,000 | 0 | 0 | ||